A Cooperative Agreement for the Interstitial Cystitis Association To Develop and Implement a Program To Enhance Interstitial Cystitis Public and Health Provider Awareness Through Partnership, Education and Communication; Notice of Intent To Fund Single Eligibility Award, 43693-43694 [05-14927]

Download as PDF Federal Register / Vol. 70, No. 144 / Thursday, July 28, 2005 / Notices containing copyrighted material, EPA will provide a reference to that material in the version of the comment that is placed in EPA’s electronic public docket. The entire printed comment, including the copyrighted material, will be available in the official public docket. Public comments submitted on computer disks that are mailed or delivered to the EPA Docket Center will be transferred to E-Docket. Public comments that are mailed or delivered to the EPA Docket Center will be scanned and placed in E-Docket. Where practical, physical objects will be photographed, and the photograph will be placed in E-Docket with a brief description written by the docket staff. You may submit comments electronically, by mail, by facsimile, or by hand delivery/courier. To ensure proper receipt by EPA, include the appropriate docket identification number with your submission. Please ensure that your comments are submitted within the specified comment period. Comments received after the closing date will be marked ‘‘late,’’ and may only be considered if time permits. If you submit comments electronically, EPA recommends that you include your name, mailing address, and an e-mail address or other contact information in the body of your comment. Also include this contact information on the outside of any submitted disk or CD–ROM, and in any cover letter accompanying the disk or CD–ROM. This ensures that you can be identified as the person submitting the comment and allows EPA to contact you in case the Agency cannot read your submission due to technical difficulties or needs further information on the substance of your comment. EPA will not edit your comment, and any identifying or contact information provided in the body of a comment will be included as part of the comment that is placed in the official public docket and made available in E-Docket. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, it may delay or preclude consideration of your comment. Electronic submission of comments to E-Docket is EPA’s preferred method for receiving comments. Go directly to EPA Dockets at http://www.epa.gov/edocket, and follow the online instructions for submitting comments. To access EPA’s electronic public docket from the EPA Internet Home Page, select ‘‘Information Sources,’’ ‘‘Dockets,’’ and ‘‘EPA Dockets.’’ Once in the system, select ‘‘search,’’ and then key in Docket ID No. ORD–2005–0022. The system is an VerDate jul<14>2003 13:40 Jul 27, 2005 Jkt 205001 ‘‘anonymous access’’ system, which means EPA will not know your identity, e-mail address, or other contact information unless you provide it in the body of your comment. Comments may be sent by electronic mail (e-mail) to ORD.Docket@epa.gov, Attention Docket ID No. ORD–2005– 0022. In contrast to EPA’s electronic public docket, EPA’s e-mail system is not an ‘‘anonymous access’’ system. If you send an e-mail comment directly to the docket without going through EPA’s E-Docket, EPA’s e-mail system automatically captures your e-mail address, and it becomes part of the information in the official public docket and in E-Docket. You may submit comments on a disk or CD–ROM that you mail to the OEI Docket mailing address. Files will be accepted in WordPerfect, Word, or PDF format. Avoid the use of special characters and any form of encryption. If you provide comments in writing, please submit one unbound original with pages numbered consecutively, and three copies of the comments. For attachments, provide an index, number pages consecutively with the comments, and submit an unbound original and three copies. 43693 PERSON TO CONTACT FOR INFORMATION: Mr. Robert Biersack, Press Officer, telephone: (202) 694–1220. Mary W. Dove, Secretary of the Commission. [FR Doc. 05–15068 Filed 7–26–05; 2:30 pm] BILLING CODE 6715–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Program Announcement AA173] A Cooperative Agreement for the Interstitial Cystitis Association To Develop and Implement a Program To Enhance Interstitial Cystitis Public and Health Provider Awareness Through Partnership, Education and Communication; Notice of Intent To Fund Single Eligibility Award Sunshine Act Notices A. Purpose The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2005 funds for a cooperative agreement program to promote public awareness and partnership, provide interstitial cystitis (IC) education for the general public and for health care providers, and develop and enhance communication channels to allow for improved interaction and information sharing among those with IC, advocates for persons with IC and their families, those who provide care and services for persons with IC, researchers, public health scientists, and the general public. The Catalog of Federal Domestic Assistance number for this program is 93.283. Federal Election Commission. PREVIOUSLY ANNOUNCED DATE AND TIME: Thursday, July 21, 2005, 10 a.m. Meeting open to the public. This meeting was cancelled. PREVIOUSLY ANNOUNCED DATE AND TIME: Thursday, July 28, 2005, 10 a.m. Meeting open to the public. This meeting was cancelled. DATE AND TIME: Thursday, August 4, 2005, at 10 a.m. PLACE: 999 E Street, NW., Washington, DC (Ninth Floor). STATUS: These hearings will be open to the public. MATTERS BEFORE THE COMMISSION: (1) State, District, and Local Party Committee Payment of Certain Salaries and Wages; (2) Definition of Federal Election Activity. B. Eligible Applicant Assistance will be provided only to Interstitial Cystitis Association, 110 N. Washington Street, Suite 340, Rockville, MD 20850. Founded in 1984, The Interstitial Cystitis Association (ICA) is a not-forprofit health organization and the national leader dedicated to providing patient and physician educational information and programs, patient support, public awareness and, most importantly, research funding for IC. ICA is the only not-for-profit national IC organization that promotes and provides funding for much needed IC research. This characteristic of ICA’s organization is unmatched by any other public or private IC health organization currently conducting similar activities in the United States. The primary mission of ICA is to research a cure and treatment for IC and provide information and Dated: July 22, 2005. Peter W. Preuss, Director, National Center for Environmental Assessment. [FR Doc. 05–14932 Filed 7–27–05; 8:45 am] BILLING CODE 6560–50–P FEDERAL ELECTION COMMISSION AGENCY: PO 00000 Frm 00015 Fmt 4703 Sfmt 4703 E:\FR\FM\28JYN1.SGM 28JYN1 43694 Federal Register / Vol. 70, No. 144 / Thursday, July 28, 2005 / Notices assistance to patients, doctors, and the general public. The ICA has over 20 years of achievement unmatched by any other health organization dealing with IC issues. Some of these achievements include: • Public awareness—the ICA has consistently attracted media attention to IC. Numerous articles featuring IC and the ICA have been published from the ‘‘New York Times,’’ ‘‘SELF Magazine,’’ ‘‘Good Housekeeping,’’ and many other national magazines. Subject-matter experts from the ICA have appeared on national TV and radio programs to include ABC’s ‘‘Good Morning America,’’ CNN, and National Public Radio. • Physician and Patient Education— Subject-matter experts from the ICA have published numerous articles on IC for professional journals including ‘‘Urology’’ and the ‘‘World Journal of Urology.’’ The ICA has worked closely with the NIDDK Division of Urology for over 15 years and has co-sponsored with the NIDDK, international scientific conferences as well as national IC patient meetings on IC biannually. ICA has also sponsored numerous regional educational programs for patients throughout the United States each year. • Patient Support—The ICA provides a toll-free 800 number designed to quickly assist both IC patients and healthcare providers. ICA also provides nationwide individual support via telephone and e-mail by ICA National Patient Support Advocates; the International IC Question Corner on its Web site, where patients can e-mail the ICA and receive one-on-one assistance with their questions; the ICA Physician Registry which helps IC patients find ICknowledgeable physicians; and IC connections, which brings together patients based on specific interests, concerns and regions, and an informational program on how to start new IC support groups. • Innovative resources—the ICA published, and continues to regularly update, a series of brochures and fact sheets as well as ‘‘IC Treatment Guidelines’’—the first comprehensive summary of IC treatments and medications designed for patients and their physicians for use as the basis for an individualized treatment plan. The ICA also publishes an on-line monthly ´ news digest, ‘‘Cafe ICA,’’ and two quarterly newsletters—the ‘‘ICA Update,’’ the only printed newsletter on IC in the United States, and the ‘‘ICA Physician Perspectives.’’ ICA also publishes a ‘‘Pocket Guide’’ series for continuing patient education. VerDate jul<14>2003 13:40 Jul 27, 2005 Jkt 205001 • Comprehensive Web Site—The ICA’s Web site http://www.icahelp.org, established in 1995, is the most comprehensive Web site on IC available today, receiving over 1.4 million hits per month. The site includes: a Clinical trials section, their on-line monthly ´ news digest—‘‘Cafe ICA,’’ IC Question Corner which provides one-on-one patient support, Treatment Options, a section for health care providers, a comprehensive research section, and much more * * *. • Non-profit leadership—the ICA remains the only United States 501 (c)(3) registered non-profit organization to fund IC research and provide educational programs on IC for both physicians and patients, as well as the public at large. This mission and ICA’s extensive network of resources and record of unmatched achievements over the last 20 years, makes it highly probable that ICA will successfully implement and complete all the required activities for this program announcement. For these reasons, the ICA is the only organization being considered for this program announcement. C. Funding Approximately $ 510,000 is available in FY 2005 to fund this award. It is expected that the award will begin on or before September 1, 2005, and will be made for a 12-month budget period within a project period of up to five years. Funding estimates may change. D. Where To Obtain Additional Information DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Advisory Committee to the Director, Centers for Disease Control and Prevention In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Advisory Committee meeting. Name: Advisory Committee to the Director, CDC. Time and Date: 8:30 a.m.–4:30 p.m., August 25, 2005. Place: Emory Conference Center, 1615 Clifton Road, Atlanta, Georgia 30329. Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people. Purpose: The committee will provide advice to the CDC Director on strategic and other broad issues facing CDC. Matters to Be Discussed: Agenda items will include updates on CDC priorities with discussions of program activities including updates on CDC scientific and programmatic activities, strategic imperatives, goals, research agenda, and health equity. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Robert Delaney, Executive Secretary, Advisory Committee to the Director, CDC, 1600 Clifton Road, NE, M/S D–14, Atlanta, Georgia 30333. Telephone (404) 639–7000. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. For general comments or questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341–4146; telephone: 770–488–2700. For technical questions about this program, contact: Richard S. Roman, Project Officer, HCAS/DACH/ NCCDPHP/CDC, 4770 Buford Hwy., N.E., MS K–51, Chamblee, GA 30341; telephone: 770–488–5144; e-mail: rsr1@cdc.gov. Dated: July 25, 2005. Diane Allen, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 05–15019 Filed 7–27–05; 8:45 am] Dated: July 22, 2005. William P. Nichols, Director, Procurement and Grants Office, Centers for Disease Control and Prevention. [FR Doc. 05–14927 Filed 7–27–05; 8:45 am] Proposed Vaccine Information Materials for Hepatitis A and Influenza Vaccines; Interim Vaccine Information Materials for Influenza Vaccines BILLING CODE 4163–18–P PO 00000 Frm 00016 Fmt 4703 Sfmt 4703 BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: E:\FR\FM\28JYN1.SGM 28JYN1

Agencies

[Federal Register Volume 70, Number 144 (Thursday, July 28, 2005)]
[Notices]
[Pages 43693-43694]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14927]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement AA173]


A Cooperative Agreement for the Interstitial Cystitis Association 
To Develop and Implement a Program To Enhance Interstitial Cystitis 
Public and Health Provider Awareness Through Partnership, Education and 
Communication; Notice of Intent To Fund Single Eligibility Award

A. Purpose

    The Centers for Disease Control and Prevention (CDC) announces the 
intent to fund fiscal year (FY) 2005 funds for a cooperative agreement 
program to promote public awareness and partnership, provide 
interstitial cystitis (IC) education for the general public and for 
health care providers, and develop and enhance communication channels 
to allow for improved interaction and information sharing among those 
with IC, advocates for persons with IC and their families, those who 
provide care and services for persons with IC, researchers, public 
health scientists, and the general public. The Catalog of Federal 
Domestic Assistance number for this program is 93.283.

B. Eligible Applicant

    Assistance will be provided only to Interstitial Cystitis 
Association, 110 N. Washington Street, Suite 340, Rockville, MD 20850.
    Founded in 1984, The Interstitial Cystitis Association (ICA) is a 
not-for-profit health organization and the national leader dedicated to 
providing patient and physician educational information and programs, 
patient support, public awareness and, most importantly, research 
funding for IC. ICA is the only not-for-profit national IC organization 
that promotes and provides funding for much needed IC research. This 
characteristic of ICA's organization is unmatched by any other public 
or private IC health organization currently conducting similar 
activities in the United States. The primary mission of ICA is to 
research a cure and treatment for IC and provide information and

[[Page 43694]]

assistance to patients, doctors, and the general public.
    The ICA has over 20 years of achievement unmatched by any other 
health organization dealing with IC issues. Some of these achievements 
include:
     Public awareness--the ICA has consistently attracted media 
attention to IC. Numerous articles featuring IC and the ICA have been 
published from the ``New York Times,'' ``SELF Magazine,'' ``Good 
Housekeeping,'' and many other national magazines. Subject-matter 
experts from the ICA have appeared on national TV and radio programs to 
include ABC's ``Good Morning America,'' CNN, and National Public Radio.
     Physician and Patient Education--Subject-matter experts 
from the ICA have published numerous articles on IC for professional 
journals including ``Urology'' and the ``World Journal of Urology.'' 
The ICA has worked closely with the NIDDK Division of Urology for over 
15 years and has co-sponsored with the NIDDK, international scientific 
conferences as well as national IC patient meetings on IC biannually. 
ICA has also sponsored numerous regional educational programs for 
patients throughout the United States each year.
     Patient Support--The ICA provides a toll-free 800 number 
designed to quickly assist both IC patients and healthcare providers. 
ICA also provides nationwide individual support via telephone and e-
mail by ICA National Patient Support Advocates; the International IC 
Question Corner on its Web site, where patients can e-mail the ICA and 
receive one-on-one assistance with their questions; the ICA Physician 
Registry which helps IC patients find IC-knowledgeable physicians; and 
IC connections, which brings together patients based on specific 
interests, concerns and regions, and an informational program on how to 
start new IC support groups.
     Innovative resources--the ICA published, and continues to 
regularly update, a series of brochures and fact sheets as well as ``IC 
Treatment Guidelines''--the first comprehensive summary of IC 
treatments and medications designed for patients and their physicians 
for use as the basis for an individualized treatment plan. The ICA also 
publishes an on-line monthly news digest, ``Caf[eacute] ICA,'' and two 
quarterly newsletters--the ``ICA Update,'' the only printed newsletter 
on IC in the United States, and the ``ICA Physician Perspectives.'' ICA 
also publishes a ``Pocket Guide'' series for continuing patient 
education.
     Comprehensive Web Site--The ICA's Web site http://
www.icahelp.org, established in 1995, is the most comprehensive Web 
site on IC available today, receiving over 1.4 million hits per month. 
The site includes: a Clinical trials section, their on-line monthly 
news digest--``Caf[eacute] ICA,'' IC Question Corner which provides 
one-on-one patient support, Treatment Options, a section for health 
care providers, a comprehensive research section, and much more * * *.
     Non-profit leadership--the ICA remains the only United 
States 501 (c)(3) registered non-profit organization to fund IC 
research and provide educational programs on IC for both physicians and 
patients, as well as the public at large.
    This mission and ICA's extensive network of resources and record of 
unmatched achievements over the last 20 years, makes it highly probable 
that ICA will successfully implement and complete all the required 
activities for this program announcement. For these reasons, the ICA is 
the only organization being considered for this program announcement.

C. Funding

    Approximately $ 510,000 is available in FY 2005 to fund this award. 
It is expected that the award will begin on or before September 1, 
2005, and will be made for a 12-month budget period within a project 
period of up to five years. Funding estimates may change.

D. Where To Obtain Additional Information

    For general comments or questions about this announcement, contact: 
Technical Information Management, CDC Procurement and Grants Office, 
2920 Brandywine Road, Atlanta, GA 30341-4146; telephone: 770-488-2700.
    For technical questions about this program, contact: Richard S. 
Roman, Project Officer, HCAS/DACH/NCCDPHP/CDC, 4770 Buford Hwy., N.E., 
MS K-51, Chamblee, GA 30341; telephone: 770-488-5144; e-mail: 
rsr1@cdc.gov.

    Dated: July 22, 2005.
William P. Nichols,
Director, Procurement and Grants Office, Centers for Disease Control 
and Prevention.
[FR Doc. 05-14927 Filed 7-27-05; 8:45 am]
BILLING CODE 4163-18-P